Human papillomavirus (HPV) vaccine: supply and demand update
Information on product options, supply, demand and pricing trends under a global context, highlighting increasing demand through UNICEF and disruptions caused by the impact of COVID-19.
Cervical cancer is the second most common form of cancer in women living in less developed regions, with an estimated 570,000 new cases a year resulting in an estimated 311,000 deaths. Eighty-five per cent of cervical cancer cases occur in low-income countries (LICs) and MICs, with sub-Saharan Africa and Asia accounting for the highest incidence rates.
This document provides a market update for human papillomavirus vaccines (HPV) that specifically targets the prevention of cervical cancer. It highlights information on product options, supply, demand, and pricing trends under a global context. It highlights increasing demand through UNICEF which could reach up to 45.5 million doses in 2021 against a globally constrained supply, which will require the postponement of some multi-age cohort vaccinations. It also calls attention to the disruptions caused to HPV immunization programmes by the impact of COVID-19.